Diversified healthcare company CVS Health (NYSE:CVS) announced better-than-expected revenue in Q1 CY2025, with sales up 7% ...

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...

CVS Health’s insurance division Aetna will stop offering plans for individuals on the Affordable Care Act exchanges in 2026, after the company projected big losses in the business this year.

Wegovy to become preferred GLP-1 drug on CVS Caremark's top formularies in 2025 as Novo Nordisk expands patient access ...

Starting July 1, Wegovy will become the preferred GLP-1 for obesity treatment on CVS Caremark’s largest commercial template ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

President Trump’s executive order provides a framework for tying the prices of U.S. pharmaceutical products to the lower ...

CVS Health Corporation ( NYSE: CVS) Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ET David Joyner - President, Chief Executive Officer Tom Cowhey - Executive Vice President, Chief Financial ...

Boosted by Microsoft's offerings, CVS intends to accelerate ... Expanding digital means CVS plans to improve its omnichannel pharmacy capabilities using Microsoft tools to provide personalised ...

Eli Lilly won’t lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an AI-powered scheduling assistant.